A2 Biotherapeutics, a biotechnology company developing innovative cell therapies for cancer patients with solid tumors, announced that it has entered into an agreement with Merck, known as MSD outside of the United States and Canada, in which A2 will continue research and preclinical development of its undisclosed Tmod™ cell therapy candidate, with the parties to co-fund A2’s clinical development and allogeneic manufacturing activities through Phase 1.